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1 The Structure of Adenoviruses. 
 
Adenoviruses belong to the family of Adenoviridae, their genome is a linear, 
double stranded DNA of about 36 kb surrounded by a protein structure with an 
icosahedral shape named capsid. They are able to infect a wide host range of post-
mitotic cells, even those in highly differentiated tissues such as skeletal muscle, 
lung, brain and heart. The Adenoviruses were first discovered more then 50 years 
ago by Rowe and colleagues from human adenoid cells (Rowe et al., 1953).  Since 
then, more then 100 different species have been identified from various species 
including chimpanzees, pig, mouse, dog and birds and all of them are 
characterized by a distinctive architecture and a common chemical composition. 
Human adenoviruses cause diseases ranging from respiratory infections and 
conjunctivitis to gastrointestinal problem. Based on their sequence homology and 
ability to agglutinate red blood cells, they are classified  into 6 subgroups (A-F), 
which are further subdivided into 51 serotypes (Lukashok, 1998). Among human 
adenoviruses, serotype 2 (Ad2) and serotype 5 (Ad5) of subgroup C are the most 
extensively studied. The adenoviral virion was morphologically characterized for 
the first time in 1993 (Stewart, 1993). It is a nonenveloped particle about 70-90 
nm in size with an outer protein shell (capsid) surrounding an inner nucleoprotein 
core (Fig. 1). The icosahedral capsid consists of 252 capsomers divided in 240 
hexons and 12 pentons. Each hexon is composed of three monomeric polypeptides 
(polypeptide II) forming the 20 triangular facets of the capsid; the penton, instead, 
shows a more complex structure, constituted by five monomeric polypeptides 
(polypeptide III), which act to anchor a trimeric protein, the fiber (polypeptide 
IV). The penton and the fiber form the penton complex that seals the capsid at 
each of the 12 virion vertices. These proteins are responsible for the attachment 
(fiber) and internalization (penton) of the virus into host cells. The only penton 
has properties like a toxin: the purified protein provokes a citophatic effect  even 
without the other viral proteins. The capsid is composed also of  a number of other 
minor components including protein IIIa, pVI, pVIII and pIX. Adenovirus cores 
contain the viral genome, a linear, double strended DNA that is approximately 36 
kb long. Each end of the genome has an inverted terminal repeat (ITR) of 100-140 
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bp with a terminal protein (TP) attached covalently (Rekosh, 1977). This protein 
protects the DNA from the endonucleases of the host cell. The genome is 
associated with other proteins like the basic protein VII and a small peptide 
termed mu (Anderson, 1989), with the function to stabilize the DNA into the 
capsid. Another protein is packaged with the DNA, the protein V. This protein is 
attached to the genome on one side and on the other side to the capsid protein VI, 
so it links the viral DNA to the capsid (Matthews, 1994). The virions contain also 
some copies of the adenovirus protease (Pr), that cleaves many of the structural 
preproteins into their mature forms during the last stage of viral assembly 
(Webster, 1989).   
 
2 Viral life cycle. 
 
2.1 Early events in adenovirus infection. 
 
The adenovirus infection can be divided into two phases. The first is named 
“early” phase and occurs in 6-8 hours. This phase comprises the entry of the virus 
into the host cell, the passage of the viral genome into the cytoplasm to the 
nucleus, the internalization of the adenoviral DNA into the nucleus and the 
transcription and translation of some viral genes, named early genes. These events 
modulate the cell metabolism to facilitate the replication of the virus DNA. The 
second phase is the “late” phase which can take about 4-6 hours after the 
beginning of the transcription of the late genes.  
The initial attachment of the virion particles to the cell surface occurs through  an 
high affinity binding between a portion of the fiber (knob domain) and a cell 
receptor. The first receptor identified was shown to be identical to that for 
Coxackie B virus and has therefore been termed coxackie/adenovirus receptor 
(CAR) (Bergelson, 1997). CAR is a type I transmenbrane protein of 46 kDa 
belonging to the immunoglobulin superfamily which is present on the basolateral 
membrane of several epithelial cells in many tissues including heart, lung, liver  
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Figure 1. Adenovirus structure. 
 
(A) A three-dimensional cryo-EM image reconstruction of Ad5 viewed along the 
3-fold axis of the icosahedral capsid (B) A stylized section of the adenovirus 
virion, indicating the relative orientations of the protein components and the viral 
DNA.  
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and brain (Fig. 2A). All groups of adenoviruses use CAR for the adsorption of the 
virus to the target cell, except the adenoviruses of group B. These viruses bind 
another cellular receptor, the CD46, a complement regulatory protein (Gaggar, 
2003). Therefore, the adenoviruses of group B are capable to infect some cells, 
like hematopoietic stem cells, dendritic cells and malignant tumor cells, which are 
resistant to the infection by the adenoviruses using CAR as the primary 
attachment receptor. All these data suggest that receptor recognition could be a 
key factor involved in cell tropism, to the point to to change it. The adenovirus 
fiber can be modified by constructing chimeric viruses carrying fiber genes from 
different serotypes, or by binding the fiber with several antibodies (Balamotis, 
2004; Cerullo, 2007). After the initial attachment of the fiber knob portion to the 
cell surface, an RGD motif, exposed on the penton base (Stewart, 1997), interacts 
with cellular αv integrins (Wickham, 1993), in presence of divalent cations. In 
particular, the heterodimeric integrins, αvβ3 and αvβ5, support the adenovirus 
internalization playing an important role in the determination of the tropism (Fig. 
2B). The interaction between adenovirus and plasma membrane can induce the 
activation of several signaling pathways like that of phosphoinositide-3-OH 
kinase (PI-3K), which triggers the Rho family of GTPases with consequential 
polymerization of actin and cythoscletal reorganization (Li, 1998). Another 
pathway, activated 20 minutes post infection, is the Raf/Mitogen-activated protein 
kinase (MAPK) pathway,  which culminates in the production of interleuchin 8 
(IL-8) (Bruder, 1997). Together, these events induce the adenovirus 
internalization through a clathrin-mediated endocytosis. In the acidic environment 
of the endosome, the virus-encoded protease mediates the dismemberment of the 
viral capsid through the proteolysis of the protein VI, which induces, in turn, the 
escape of virions to the cytoplasm. The passage through the cytoplasm to the 
nucleus seems to be mediated by the cellular protein p32 (Matthews, 1998), which 
binds the virus core (constituted by the DNA and its associated proteins TP, mu, 
proteins VII and V), and involves dynein and microtubules (Leopold, 2000). One 
hour after the infection, it is possible to detect the virion on the nuclear 
membrane. Once inside the nucleus, the viral genome is targeted to the nuclear  
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Figure 2. Adenovirus interaction with cell surface.  
(A) Schematic representation of adenoviral fiber with the cell receptor, CAR. (B) 
The second adenoviral interation between the penton and the αv integrins to allow 
virus internalization. 
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matrix, where TP forms a complex with the cellular CAD pyrimidine synthesis 
enzyme (Angeletti, 1998)  and p32 binds the nuclear lamin B to permit the 
dissociation between the viral DNA and the linked proteins. 
 
2.2 Early gene and DNA replication. 
 
The transcription of adenoviral genes can be divided in two phases, early and late, 
respectively occurring before or after viral DNA replication (Fig. 3). The first 
viral transcribed gene is E1, which encodes for two products: E1A and E1B, each 
of them producing multiple proteins by way of differential mRNA processing. 
Two E1A transcripts are produced during early infection, encoding the 289R 
protein and 243R protein. These proteins have the function to modulate the 
cellular metabolism to make the cell more susceptible to virus replication. In order 
to do this, they act as trans-activators on the other early adenovirus genes and 
induce the cells to enter in S phase (Berk, 1986). Indeed, both 289R and 243R 
protein are able to sequester Rb protein (Retinoblastoma protein), bounded to the 
transcriptional factor E2F, allowing the release of this factor and the activation of 
its target genes necessary for driving the cell into S phase (Harlow, 1986). 
Moreover, E1A proteins can also bind proteins involved in the control of cell 
cycle, such as cyclin-dependent-kinase-inhibitor p21, or factors mediating 
chromatin structure like p400, pCAF and p300/CBP. The E1B gene product 55K 
(E1B-55K) acts blocking p53-dependent apoptosis by directly binding p53, 
accumulated during cell cycle deregulation by E1A, and inhibiting its ability to 
induce expression of proapoptotic genes (Ben-Israel, 2002). Instead, the other 
product of E1B gene, E1B-19K, blocks the pathway of programmed cell death 
binding directly the proapoatotic proteins Bak and Bax (Sundararajan, 2001). 
These mechanisms keep the cell alive as long as possible in order to permit the 
virus replication.  
The E2 gene products (E2A and E2B) are proteins that are necessary for the 
replication of viral genome and the ensuring transcription of late genes. The 
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latters are a DNA polymerase, the preterminal protein (pTP) and the 72-kDa 
single stranded DNA binding protein (DBP). 
The E3 gene expression is indispensable for subverting the host defence 
mechanism, allowing the persistence of infected cells. Indeed, the E3-gp19K can 
interfere with the presentation of the viral antigen, preventing the translocation of 
MHC class I (major histocompatibily complex) molecules to the cell surface by 
sequestering them in the endoplasmic reticulum (Bennett, 1999). Moreover, the 
E3-10.4K, 14.5K and 14.7K proteins inhibit the apoptotic pathway inducing the 
clearance of TNF-α, Fas ligand (FasL) and TRAIL receptors from the cell 
membrane.  
The gene products derived from the E4 cassette are involved in cell cycle control 
(E4orf6 cooperates with the E1B-55K protein in the sequestration of p53), 
promote virus replication and shut-off the host protein synthesis (Querido, 2001). 
During the last steps of early phase of the adenovirus infection, the viral DNA 
replication begins but requires sequences within the ITRs as origin of replication. 
Moreover, because the viral genome does not have telomeres, the integrity of 
DNA ends is ensured by the viral protein pTP. This protein is covalently linked to 
the 5’ end of each genome strand and acts as a primer for the viral DNA 
polymerase. The genes are encoded on both strands of DNA in a series of 
overlapping transcription units.    
 
2.3 Late gene expression and viral assembly. 
 
After viral DNA replication, the transcription of late genes begins (Fig. 3). A key 
role in the control of this phase is played by the major late promoter (MLP), 
which is attenuated during the early stage of infection. In fact, during the “early 
phase”, the basal level of transcription is low while, after the viral DNA 
replication and the high expression of IVa2 and IX genes, the transcription via the 
MLP is fully functional. From the MLP, 5 genes (L1-L5) are transcribed as single 
pre-mRNAs, each one encoding from 15 to 20 different mRNAs by differential 
splicing and polyadenylation. These transcripts encode structural proteins and 
other proteins involved in virion assembly.  
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Figure 3. Schematic representation of genome and transcription 
units.  
 
The central, solid line represents the viral genome. Positions of the left and right 
ITRs, the early transcription units (E1A, E1B, E2, E3, and E4), and the major late 
transcription unit (major late promoter (ML), L1–L5) are shown. Arrows indicate 
the direction of transcription. 
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The virion assembly takes place in the nucleus, but the hexon trimerization begins 
in the cytoplasm and, subsequently, the hexon trimers move to the nucleus where 
they are associated with pentons and minor proteins to form the capsid (Cepko, 
1983). The viral genome encapsidation requires the L1-52/55K, IVa2, L4-33K 
proteins (Hasson, 1989; Zhang, 2003; Fessler, 1999) and the packaging signal, 
which consists in a series of seven repeats (A1-A7), enriched in AT, at the left end 
of the adenoviral DNA . These events are accompanied by changes in the nuclear 
structure. About 30 hours after infection, the host cell is lysed in a process 
involving the ADP protein (adenovirus death protein), a product of E3 gene, 
which is expressed only during the late phase of infection and is transcribed from 
MLP rather than E3 promoter (Tollefson, 1996). 
 
3 Adenoviruses as vectors. 
 
3.1 First and second generation of adenoviral vectors. 
 
The adenoviruses can be used in the gene therapy field as vectors carrying the 
therapeutic gene into target cells, where the same gene is defective.  In fact, it is 
possible to take advantage by  the natural ability of virus to infect and deliver their 
genes to human cells in a pathogenic manner. Handling their genome, it has been 
possible to obtain several adenoviral vectors: first generation vectors (FG-Ad), 
second generation vectors and helper dependent vectors (HD-Ad).  
In the first generation vectors, the E1 and/or E3 genes cassette are removed,  
resulting in viruses that are impaired in their ability to replicate (replication 
deficient adenoviral vectors, RDA) (Fig. 4). These vectors retain the ITRs, the 
packaging signal and the other genes whereas the E1/E3 cassettes are  replaced by 
a transgene of 6-8 kb long, often under the control of a heterologous promoter. 
The production strategy of  FG-Ad vectors consists in the generation of  the 
adenoviral genome by homologus recombination between a backbone plasmid 
(pAdEasy), expressing all adenovirus genes except E1 and/or E3, and a plasmid 
shuttling the gene of interest (He, 1998) (Fig. 5). When vector genome is 
obtained, its large scale production is possible using the HEK-293 cell line, a 
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human embryonic kidney-derived cell line, that provide the E1 functions in trans 
(Graham, 1977). Although the FG-Ad vectors exhibit many advantages, as their 
ability to infect post-mitotic cells in highly differentiated tissues,  liver tropism 
after systemic administration and high title production (1x1013 vp/ml), some 
troubles exist with their use. In fact, during the vector production, a recombination 
between the E1 region sequences in the packaging cells (HEK-293) and the 
recombinant virus can give rise to viral progeny with functional E1 genes, that are 
replication competent adenovirus (RCA) (Lochmuller, 1994). The second and 
more troublesome problem associated with the use of FG-Ad vectors consists in 
their stimulation of the host immune response. This response is due to low levels 
of vector replication, that can occur even in the absence of the E1 genes (Yang, 
1994), resulting in the destruction of transduced cells and in the low persistence of 
transgene. In order to prevent these problems, a second generation (SG-Ad) 
vectors has been produced (Fig. 4). These vectors are characterised by deletion of 
E2 and/or E4 coding sequences, providing both the benefits of a less probability 
of recombination to give RCA and a larger capacity for the transgene insertion. 
Nevertheless, the inhibition of viral gene expression by E1 gene is not much 
efficient. For this reason, the host immune response is a major impediment in 
using these vectors for applications requiring long-term gene expression. 
 
3.2 Helper-dependent vectors. 
 
To improve the safety and efficiency of Ad-based vectors, other vectors have been 
constructed: the helper-dependent adenoviral vectors (HD-Ad). These vectors are 
deleted of all viral coding sequences (hence they are called also gutless) while 
only the two ITRs and the packaging signal is left. Because efficient packaging 
into the Ad capsid requires a genome size between 28 kb and 38 kb, stuffer DNA 
is introduced in HD-Ads. The nature of this stuffer DNA is noncoding 
mammalian DNA with minimal repeat sequences. Moreover, because HD-Ad 
vectors are deleted of all viral coding sequences, all proteins for vector replication 
and assembly are required in trans. Accordingly, for their propagation these 
vectors need a virus helper, a particular FG-Ad vector bearing packaging signal  
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Figure 4. Schematic representation of adenoviral vectors. 
(A) Adenovirus genome. (B) First generation adenoviral vectors. (C) Second 
generation adenoviral vectors. 
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Figure 5. Schematic representation of First generation adenoviral 
vectors production. 
 
A plasmid expressing the transegene of interest (pShuttle) is recombinated with a 
backbone plasmid (pAdEasy), expressing all adenovirus genes except E1 and/or 
E3. After the homologous recombination, the pAd vector is linearized and 
tranfected in 293 cells to proceed with the large scale production of vector. 
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Figure 6. Schematic representation of Helper dependent 
adenoviral vectors production. 
 
A plasmid expressing the transgene of interest is transfected in 293 Cre cells and 
subsequently the cells are infected with a virus Helper. The Cre recombinase 
mediates site specific recombination between loxP sites, that flanked the 
packaging signal of the Helper virus, rendering the helper viral genome 
unpackageable but still able to trans-complement the replication and the 
encapsidation of the HD-Ad genome 
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flanked by loxP sites, the target sequences for the recombinase Cre (Parks, 1996) 
(Fig. 6). The packaging cell line 293Cre are transfected with linearized HD-Ad 
genome and subsequently infected with the helper virus. After the infection, the 
packaging signal of the helper virus is excised by Cre-mediated site specific 
recombination between loxP sites, rendering the helper viral genome 
unpackageable but still able to trans-complement the replication and the 
encapsidation of the HD-Ad genome. The large scale production of a HD-Ad 
vector is carried out by several coinfections of 293Cre cells with HD-Ad and the 
helper virus. Finally, the HD-Ad vector is purified on CsCl gradient 
ultracentifugation. To obtain large quantities of HD-Ad vectors with a low helper 
virus contamination (a necessary condition for in vivo approaches) the Cre –loxP 
method is improved by Ng (Palmer, 2003). The new strategy of production 
consists in the use of a suspension-adapted cell line (116Cre) expressing higher 
levels of Cre than 293Cre cells. The helper virus should have a longer DNA 
insertion into the E3 region, such to render its genome large enough to permit a 
physical separation from HD-Ad after the CsCl purification. Moreover, the helper 
virus presents the packaging signal in an orientation opposite to that of HD-Ads, 
so that the possibility of homologous recombination between these two elements 
is reduced and, in turn, also the generation of RCAs.  These improvements allow 
to produce, in about two weeks, more then 1x1013 viral particles per ml (vp/ml) 
starting from 3 liters of cells (3–4x108 total cells), with a helper virus 
contamination, after CsCl purification, of about 0,02 - 0,01%, as determined by 
DNA-based assay. 
The HD-Ad vectors retain several advantages of FA-Ads, including a high 
efficiency of in vivo liver transduction, after their systemic administration, and a 
high level of transgene expression. Moreover, the deletion of the viral genes 
permits a large cloning capacity of about 37 kb, allowing the insertion of whole or 
multiple genes and large cis-acting elements to enhance, prolong and regulate 
transgene expression (Morral, 1998). The absence of viral genes in transduced 
cells makes the HD-Ad vectors able to mediate high levels, long term transgene 
expression in absence of chronic toxicity (Schiedner, 1998). However, some 
aspects of toxicity persist also with the use of HD-Ad vectors. 
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3.3 Immune response to Ad based vectors. 
 
Although the HD-Ad vectors are compelling candidates for gene therapy 
application, the immune response to the vector is a major impediment to their use 
in clinical, because it leads to the elimination of the vector and the transfected 
cells, decreasing both the intensity and the duration of transgenic protein 
expression. In addition, the memory response would then thwart further efforts to 
use the same vector or transgene. However, when the goal is vaccination or tumor 
lysis, this response may be beneficial.  
The immune response induced by intravenous delivery of Ad vectors revealed a 
biphasic response comprised of an early or acute phase and a late or chronic phase 
(Fig. 7). The former is due to the activation of the innate immune system, mainly 
consisting of a rapid (few hours) inflammatory cytokines and chemokines 
secretion; the latter is the adaptive immunity, leading to antibodies production and 
T lymphocytes activation in a few days after vectors administration. These two 
phases are induced by different portions of Ad: the expression of proinflammatory 
mediators occurs before substantial viral gene transcription, suggesting that the 
adenoviral capsid triggers this response (it is induced by FG-Ad, HD-Ad vectors 
and ultraviolet/psoralen inactivated Ad vectors) (Liu, 2003; Muruve 2003); on the 
other hand, the adaptive response in not observed after the administration of HD-
Ad and inactivated vectors, confirming that viral gene transcription is required for 
this response. 
Immediately after the injection of Ad vectors, the Ad particles interact with cells 
and proteins in the blood. The interaction with neutrophils, macrophages, dendiric 
cells, NK cells and complement lead to initiate and sustain the cascade of 
proinflammatory cytokines. In particular, granulocytes such as neutrophils, 
represent the main source of cytokines; NK cells are interferon α/β responsive 
cells that perform cytolytic functions; NK and T cells, via IL-12 and IL-18, 
secrete interferon γ that is essential in the development of helper T cell type 1 
(Th1). Finally, monocytes/macrophages are phagocytes that not only secrete 
antiviral cytokines but also present the antigen required for adaptive immunity. 
Moreover, the interaction with C3 complement leads to activation of neutrophils 
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and rapid release of the chemokines, which further recruits and activates 
inflammatory cell infiltrate to the circulatory system (Cotter, 2005; Kiang, 2006). 
Ad also interacts directly with CAR receptor present on platelet cell surface, 
causing platelets activation with increased levels of D-dimer and up-regulation of 
adhesion molecules like ICAM-1 and VCAM-1 (Othman, 2007; Baker, 2007). 
These molecules allow an increased adhesion and migration of infiltrating 
leukocytes, and extensive platelet/leukocyte aggregation, leading to clearance of 
activated platelets by scavenger macrophages. For this reason, the most consistent 
markers of immune activation are the increased levels of systemic cytokines (IL-
6, IL-12, TNF-α, RANTES, MCP-1, IFN-α) and thrombocytopenia. Within 24 
hours, the innate response eliminates about 80% of adenoviral particles. At 
molecular level, different pathways recognize viral pathogens and induce 
secretion of cytokines (Fig. 8). The first type of viral innate immune response 
sensor belongs to RNA helicase family and includes RIG-1 and MDA-5, which 
are ubiquitously expressed in the cytosol. The recognition of RNA by these 
helicases results in the recruitment of the adaptor protein MAVS, which 
stimulates the TANK-related kinases TBK1 and IKKε, leading to the 
phosphorylation of IRF3 and IRF7, the main transcription factors of type I 
interferons. A similar signalling network is crucial in sensing Ad infections, 
leading to activation of IRF3, through specific cytosolic sensor of foreign DNA 
(Nociari, 2007). Another set of molecular sensors includes the family of pattern 
recognition receptors called Toll-like receptors (TLR), which are expressed 
primarily on the cell membrane or in the endosomal compartment of macrophages 
and DC. They are single spanning transmembrane proteins that can be in 
homodimeric or heterodimeric form, suggesting that the diversity of their pattern 
of recognition may be increased by combinatorial interactions (Akira, 2006). 
However, TLR3, TLR7/8 and TLR9 recognize dsRNA, ssRNA and dsDNA 
respectively; TLR4 mediates the recognition of LPS; TLR2 is important for the 
response to cytomegalovirus and measles virus. Engagement of a TLR family 
member initiates a network of signalling cascades, involving the intracellular 
adaptor proteins MyD88 and/or TRIF. In particular, MyD88 activates the proteins 
of IRAK family and TRAF6, leading the activation of TAK1, which in turn 
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activates the IkB kinases. So, the transcription factor NFkB translocates to the 
nucleus and induces the expression of several cytokines. Another consequence of 
IRAK signalling is the phosphorylation and activation of the transcription factors 
IRF3 and IRF7, which also induce and/or regulate secretion of inflammatory 
cytokines (Kaisho, 2006). Recently, it has been shown that TLR9 is a sensor of 
dsDNA of HD-Ad backbone in primary macrophages, a finding which is 
consistent with its localization in the endosamal compartment, where capsid 
dissociation is thought to occur. Moreover, the TLR9 mRNA is upregulated 
during the early phase of viral infection, suggesting that it may predispose APCs 
to sensing the invading pathogen (Cerullo, 2007). At the moment, it is unknown 
whether a putative “surface sensor” of the viral capsid may work together with the 
intracellular sensors. However, the innate immune response to adenoviral vectors 
is dose dependent: a higher dose of the adenoviral vector induces a stronger 
inflammatory response, which accounts for the elimination of infected cells and 
leads to a decrease in transgene expression. This plateau effect is probably 
attributable to saturation of adenovirus receptors such as CAR. 
Four-five days after the intravenous administration of Ad vectors, the adaptive 
immune response is activated. It consists of two components: a cellular immune 
and a humoral response (Fig. 9). In general, the former is activated by antigen 
presenting cells (APCs) that, after the uptake of the Ad, process the viral proteins 
and present them at the major histocompatibility complex (MHC) class I, on the 
cell surface (Kafri, 1998). Once the MCH-I is loaded with viral proteins, it binds 
to the CD8+ T cells and, in the presence of a co-stimulatory signal (the interaction 
between CD28 and B7), activates them in order to form cytotoxic T lynphocytes 
(CTL) which finally destroy the transduced cells. The cellular immune response is 
further stimulated by CD4+ cells, belonging to the Th1 subset. These cells are 
activated by epitopes presented by MHC class II molecules at the surface of 
APCs, whose activation triggers the secretion of IL-2 and INF-γ. These cytokines, 
in turn, induce the differentiation of CD8+ T cells into CTLs and the up regulation 
of MHC-I expression in Ad transduced cells, consequently facilitating their 
recognition by CTLs. Apart from the cellular immune response, the adaptive 
immune system also induces a humoral response that is initiated by the binding of 
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Ad particles to the surface immunoglobulin of B cells. After internalization and 
processing of the virus, the Ad epitopes are presented at the surface of B cells by 
MHC II molecules where they are recognized by activated T helper cells of the 
Th2 subset. These specific CD4+ cells release cytokines like IL-4, IL-5, IL-6 and 
IL-10, which provide signals for the B cells to differentiate into plasma cells. The 
plasma cells secrete antibodies (Abs) directed towards the adenoviral capsid, 
preventing the Ad cell entry and promoting the opsonisation by macrophages. 
Consequently, these Abs hamper the efficiency of repeated administration of 
adenoviral vectors. 
The HD-Ad vectors induce a weaker T cell response, compared to FG-Ads, 
because of the deletion of adenoviral genes. However, even in the absence of viral 
transcription, a cytotoxic T cell response can be induced by these vectors. This 
response may be ascribable to the immunogenicity of adenoviral capsid proteins, 
that also promote the innate response. Hiding the viral capsid, it could be possible 
to escape the host immune response.    
 
3.4 PEGylation and preliminary data.   
 
Adenoviral vectors are promising candidates for in vivo delivery of several 
therapeutic genes, but their systemic administration leads to the activation of 
innate and antigen specific immunity. Different strategies have been proposed to 
block the immune response, such as the induction of tolerance by oral 
administration of the virus (Ilan, 1999) or the administration of viruses to neonatal 
animals (Walter, 1996). However, in both cases, complicated treatment protocols 
should be required and, moreover, these should not be viable treatments in case of 
therapy of patients with severe pathological diseases. Successful results in 
modulating the immune response against Ad vectors have been obtained using 
pharmacological regimens designed to produce a general immunosuppression, 
including treatment with cyclophosphamide (Kuriyama, 1999), FK506 and 
cyclosporine A (Fang, 1995). Although these agents reduce the formation of 
neutralizing antibodies against viral capsid proteins, they can produce significant 
untoward side effects and impair pre-existing immunity to other pathogens. For  
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Figure 7. Representation of immune response to adenoviral 
vectors. 
 
Complex bloodborne protein and cellular factors interact with HDV within 
minutes of systemic administration (bottom). The cascade of inflammatory 
mediators initiated by the immediate cellular interactions (middle) exacerbates the 
clinical manifestations shown (top) over several hours. The induction of innate 
immune responses initiated days earlier, leads to activation of antigen presenting 
cells and subsequent 
TH1/2 cell expansion, and an anti-transgene humoral immune response to the 
virus and transgene. 
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Figure 8. Molecular components of the innate cell-associated 
sensors of adenoviral infection. 
 
Several components are responsible for the innate response to adenoviral vectors. 
The most important pathway involved in the production of cytokines are 
dependent by TLR and cytosolic sensors. 
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Figure 9. Activation of the host’s immune system upon adenoviral 
gene transfer.  
 
Antigen-presenting cells (APCs) process de novo synthesized viral proteins or 
transgene products and present these to CD8+ T cells by means of MHC class-I 
molecules. This causes the CD8+ T cells to form cytotoxic T lymphocytes (CTL), 
which specifically destroy the transduced target cells. The proliferation of CTLs is 
further stimulated by CD4+ helper cells of the Th1 subset. Their activation is 
triggered by epitopes from the input virus, which are presented by MHC class-II 
molecules on the cell surface of APCs. Apart from the cellular immune response, 
CD4+ T helper cells also participate in the activation of the humoral immune 
response. Binding of the Ad vector to B cells and interaction with an activated T 
helper cell induce B cells to differentiate into plasma cells. The subsequent 
production of Ad-specific neutralizing antibodies limits the beneficial effect of a 
repetitive administration of the same Ad vector by blocking its cellular entry. 
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this reason, chemical modification of viral capsid proteins, with the use of 
polyethylene glycol (PEG) (PEGylation), has been recently proposed as an 
alternative way to effectively ablate immune responses to adenoviral vectors. PEG 
is an uncharged, hydrophilic, non immunogenic polymer, with low toxicity. 
Moreover, it is approved by the Food and Drug administration (FDA) for use in 
drugs, foods and cosmetics. Currently, five PEG modified proteins are used in 
clinic: PEG-L-asparaginase, PEG-superoxide dismutase, PEG-adenosine 
deaminase, PEG-interleukin 2 and PEG- α-interferon, and in most cases, these 
proteins have shown improved therapeutic efficiency with enhanced circulation 
half life in vivo, reduced immunogenicity , enhanced solubility and suitable in 
vivo bioactivity. Indeed, PEGylation provides a hydrophilic coat to therapeutic 
molecules to protect them from proteolytic degradation and immune response, 
permitting an increase in the persistence of these proteins in the blood. The PEG 
can react also with the ε-amino terminal of lysine residues on the adenoviral 
capsid proteins, leading to a stable, secondary amine linkage. Different types of 
PEGs, differing in their molecular weight, can be used in this approach, but 
everyone binds the major structural Ads proteins (hexon, penton, base and fiber), 
that are the only proteins modified (O’Riordan, 1999). For this reason, factors, 
such as concentration of activated PEG, length of time of PEGylation and pH, can 
influence the retention of infectivity of PEGylated vectors. Indeed, a large number 
of PEG chains can couple to lysine residues in fiber knob and/or penton base and 
eventually may compromise the ability of the virion to interact with receptors on 
the cell surface. The modification of only 70% of available lysines results in a 
vector that efficiently evades the immune response, maintaines the highest title 
and its transduction efficiency (Croyle, 2000). Several studies on PEGylated Ad 
vectors have demonstrated a reduction in both innate and adaptive response in 
mice, both with the use of FG-Ad and HD-Ad vectors (O’Riordan, 1999; Croyle 
2002;  Croyle 2005): 1) 6 hours after systemical injection of the PEGylatd vectors, 
the levels of serum cytokines were reduced,,compared to treatment carried out 
with unmodified vectors; 2) 3 days after administration of PEGylated vector, no 
signs of thrombocytopenia were observed; 3) PEGylation of vectors also 
diminished the activation of cytotoxic T lymphocytes, helper T cells and the 
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production of neutralizing antibodies. These effects are due to a lesser recognition 
of the vector by macrophages, involved in the initial activation of both innate and 
adaptive immune response, but it is unknown the specific mechanism of PEG 
action and, in particular, the receptor/s on cell surface that is/are involved in the 
interaction with PEG. However, the PEGylation vectors show the same 
transduction efficiency of the unmodified vectors, associated with the possibility 
to readminister the native virus. All these advantages of PEGylated vectors render 
supposable their use in clinical trials. 
 
4 Atherosclerosis. 
 
4.1 Lipoprotein metabolism. 
 
Lipoproteins are spherical particles present in blood plasma, containing a central 
core of non-polar lipids (triglycerides and cholesteryl esters) and a monolayer 
surface of polar lipids (phospholipids) and apoproteins. Reflecting the relative 
amounts of different lipids and proteins, the density of these particles is inversely 
related to their size and, so, it is possible to separate them in six main classes. The 
two largest classes, which contain mainly triglycerides in their core, are 
chylomicrons and VLDL (very low density lipoproteins). Instead, the smallest 
lipoprotein classes, LDL (low density lipoproteins) and HDL (high density 
lipoproteins) contain cholesteryl esters in their cores, while IDL (intermediate 
density lipoproteins) have an appreciable amount of both triglycerides and 
cholesterol.  
Chylomicrons are synthesized and assembled in the endoplasmic reticule of 
enterocytes, beginning from dietary fatty acids, as triglycerides (Fig. 10 ). Then, 
they are transported to the Golgi apparatus, where the nascent lipoproteins are 
packaged in secretory vesicles and delivered into the extracellular space by 
exocytosis. The beginning protein components include the apolipoprotein B-48 
(ApoB-48) and ApoA-I, A-II and A-IV, but after the secretion they acquire ApoC-
II and ApoE by transfer from HDL. Into the blood, chylomicrons bind to 
lipoprotein lipase, expressed on the surface of capillary endothelial cells that, in 
 - 25 - 
presence of ApoC-II, mediates the hydrolysis of triglycerides. Concomitantly, 
some phospholipids, ApoC and ApoA are transferred to HDL: the residual 
particles are called chylomicrons remnant. The recognition of a domain on ApoE 
allows the binding of the remnants to LDL receptors on hepatocytes and so their 
endocytosis and catabolism in lysosomes. The cholesterol released from 
lysosomes in hepatocytes can enter in pathways leading to formation of bile acids.  
VLDL provide a pathway for export from hepatocytes of excess triglycerides and 
they are synthesized in the liver as a particles containing also ApoB-100 and small 
amounts of ApoE and C (Fig. 10 ). After secretion, additional amounts of the 
latter proteins are added and VLDL triglycerides are hydrolyzed in extrahepatic 
tissues by lipoprotein lipase to yield remnant particles. LDL receptors on 
hepatocytes recognize ApoE on VLDL remnants and mediate the endocytosis of a 
substantial fraction of these particles. Some particles, however, are further 
processed to IDL and then LDL that can be taken up by the same liver receptors 
(which recognize ApoB-100) or by LDL receptors on extrahepatic cells, even if 
the liver is the principal site of removal of LDL from the blood.  
The plasma HDL are assembled extracellularly as surface components of 
triglyceride-rich lipoproteins, including phospholipids and cholesterol (Fig. 10 ). 
These components are transferred to pre-existing HDL particles from extrahepatic 
cells, and the cholesterol can be esterified by LCAT (lecithin-cholesterol 
acyltransferase) in presence of its main cofactor ApoA-I. The cholesteryl esters 
produced are rapidly transferred to other lipoproteins to be taken up into liver via 
the receptors mediated endocytosis. Therefore, the HDLs can be considered as the 
main particles involved in the reverse cholesterol transport, the process that 
mediates the transfer of cholesterol from extrahepatic tissue to the liver. 
 
4.2 Plaque progression in atherosclerosis. 
 
Atherosclerosis is an inflammatory process characterized by the deposition of 
lipid and other blood borne material within the arterial wall, that lead to the 
development of complex lesions, or plaques, protruding into the arterial lumen. 
Plaque rupture and thrombosis result in the acute clinical complications of  
 - 26 - 
 
 
 
 
 
 
 
 
Figure 10. Schematic view of cholesterol metabolism and reverse 
cholesterol transport.  
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myocardial infarction and stoke. Among the several genetic and environmental 
risk factors, elevated level of serum cholesterol is probably the unique feature 
being sufficient to drive the development of atherosclerosis in humans and 
experimental animals.  
The atherosclerosis lesions begin as a fatty streaks underlying the endothelium of 
large arteries, in particular in areas characterized by low shear rate and/or flow 
disturbances (bifurcation and branching points). Endothelial dysfunction has a 
considerable importance at the beginning of this process, because this dysfunction 
is characterized by a functional disruption of the protective endothelium, 
unleashing not only the internalization of cholesterol, but also the recruitment of 
inflammatory cells into the vessel wall, initiating the atherosclerosis process (Fig. 
11). At vascular level, the endothelial dysfunction is characterized by the 
synthesis and exposure of adhesive proteins (VCAM, ICAM, P and E selectin), 
facilitating the homing and internalization of the circulating monocytes and lipids 
into the intimal layer. Cholesterol accumulation plays a central role in 
atherogenesis: LDL can undergo oxidative modifications in the lipids and Apo-B, 
that can range from minimal modification (mmLDL) in which the LDL can still 
be recognized by LDL receptor, to extensive oxidations, that preclude the binding 
to the receptor. While LDL is protected from oxidation in the plasma 
compartment, it is thought that its retention by extracellular matrix proteins in the 
artery wall render it susceptible to enzymatic and nonenzymatic modifications. 
The presence of the oxidized lipids triggers a series of proinflammatory reactions 
via different mediators (TNF-α, IL-1, MCS-F), perpetuating the activation and 
recruitment of monocytes macrophages and inflammatory cells. Although the 
recruitment of monocytes to the arterial wall and their subsequent differentiation 
in macrophages may initially serve a protective function, by removing cytotoxic 
and proinflammatory oxidated LDL (oxLDL), progressive accumulation of these 
cells and their uptake to oxLDL ultimately leads to development of atherosclerotic 
lesions. In fact, macrophages, by accumulation of massive amounts of cholesterol 
esters, become foam cells. The uptake of cholesterol in these cells is mediated by 
scavenger receptors, that recognize oxidized phospholipids both in lipid phase and 
Apo-B. The macrophages have two potential mechanisms for depositing the 
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excess of cholesterol: enzymatic modification by cholesterol 27 hydroxylase, for 
converting it into a more soluble form, or the efflux via membrane transporters. 
The latter is the major mechanism with the HDL being the primary extracellular 
acceptor of cholesterol: this explains why risk of atherosclerosis is inversely 
correlated with the levels of HDL cholesterol. Once cholesterol has been taken up 
from HDL, it enters in the reverse transport of cholesterol and, so, it can be 
esterified by LCAT. At this point, HDL can exchange cholesterol esters for 
triglycerides carried by other lipoproteins via cholesterol ester transfer protein 
(CETP). Although the HDLs are the principal actors in reverse transport of 
cholesterol,  ApoA-I is the real responsible for metabolic fate of HDL cholesterol, 
accounting for 70% of HDL protein content. Therefore, the overexpression of 
ApoA-I has a protective role in atheroscelrotic progression.  
The transition from a fatty streak to a more complex lesion is characterized by the 
immigration of smooth muscle cells from the medial layer of the artery wall to the  
intimal space (Fig. 12). Here, the smooth muscle cells may proliferate and take up 
modified lipoproteins, contributing to foam cells formation. Moreover, they 
synthesize extracellular matrix proteins that lead to the development of the fibrous 
cap. This phase of lesion development is influenced by the interaction between 
monocytes and activated T cells. The consequent cellular and humoral responses 
result in a chronic inflammatory state that, in association with the oxidized sterols 
present in oxLDL, appears to promote apoptosis and necrosis processes. 
Apoptosis of macrophages and vascular smooth muscle cells results from cell-cell 
interactions and the local cytokine environment within the arterial wall, involving 
the actions of pro and anti apoptotic proteins which include death receptors, proto 
oncogenes and tumor suppressor genes (Fig. 13). The necrotic cells release 
oxidated and insoluble lipids and matrix metalloproteases, that may influence the 
plaque stability and its rupture. Plaque rupture exposes plaque lipids and tissue 
factor to blood components, initiating the coagulation cascade, plaque adherence 
and thrombosis. These events are associated with acute myocardial infarction.  
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Figure 11. Initiating events in the development of a fatty streak 
lesion. 
 
LDL is subject to oxidative modifications in the subendothelial space, progressing 
from minimally modified LDL (mmLDL), to extensively oxidized LDL (oxLDL). 
Monocytes attach to endothelial cells that have been induced to express cell 
adhesion molecules by mmLDL and inflammatory cytokines. Adherent 
monocytes migrate into the subendothelial space and differentiate into 
macrophages. Uptake of oxLDL via scavenger receptors leads to foam cell 
formation. OxLDL cholesterol taken up by scavenger receptors is subject to 
esterification and storage in lipid droplets, is converted to more soluble forms, or 
is exported to extracellular HDL acceptors via cholesterol transporters, such as 
ABC-A1. 
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Figure 12.  Lesion progression. 
 
Interactions between macrophage foam cells, Th1 and Th2 cells establish a 
chronic inflammatory process. Cytokines secreted by lymphocytes and 
macrophages exert both pro- and antiatherogenic effects on each of the cellular 
elements of the vessel wall. Smooth muscle cells migrate from the medial portion 
of the arterial wall, proliferate and secrete extracellular matrix proteins that form a 
fibrous plaque. 
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Figure 13. Plaque rupture and thrombosis. 
 
Necrosis of macrophage and smooth muscle cell–derived foam cells leads to the 
formation of a necrotic core and accumulation of extracellular cholesterol. 
Macrophage secretion of matrix metalloproteinases and neovascularization 
contribute to weakening of the fibrous plaque. Plaque rupture exposes blood 
components to tissue factor, initiating coagulation, the recruitment of platelets, 
and the formation of a thrombus. 
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4.3 Animal models for atherosclerosis and preliminary data.  
 
The ideal animal model of atherosclerosis should mimic the human subject, 
metabolically and pathophysiologically, and also develop lesions comparable to 
those found in humans. However, atherosclerosis is a complex multifactorial 
process, so no specie would ever be suitable for all studies. Mouse, for example, is 
an animal model largely used in the research but its differences with humans 
render complicate the translation of experimental results obtained with it. For 
example, the different lipid metabolism and gene expression make the wild type 
mice very resistant to the development of atherosclerosis. In fact in the mouse 
model, unlike humans, the primary circulating lipoprotein is the 
antiatherosclerosis HDL and the levels of LDL and VLDL are very low. 
Moreover, murine features like the location of atherosclerotic plaques (aorta in 
mice versus coronary arteries in humans), the course of the disease (fulminate in 
mice versus indolent in humans), the absence of end-stage ischemic lesions, as 
well as the fact that murine atherosclerosis is not associated with occlusive 
coronary artery disease, myocardial infraction, cardiac dysfunction, and premature 
death, which are the hallmarks of human coronary heart disease, might hinder the 
translation of the findings from mice to humans. Although mice are normally 
resistant to develop atherosclerosis, all of the current mouse models are based on 
perturbation of lipoprotein metabolism through both genetic manipulations and 
dietary. The most used mouse models are apolipoprotein E deficient mice   
(ApoE-/-) and LDL receptor deficient mice (LDLR-/-). The ApoE-/- mice show a 
pronounced increase in the plasma levels of atherogenic lipoproteins, due to the 
failure of LDL receptor to mediate clearance of these lipoproteins. Moreover, 
even on a standard chow diet, which is low in its fat content,  these mice have a 
spontaneous development of atherosclerotic lesions that can be strongly 
accelerated by a high fat diet. Nevertheless, the ApoE-/- mouse model has a 
considerable limitation because plasma cholesterol is confined to VLDL and not 
to LDL particles as in humans. However, these mice are used in gene therapy as a 
model of familial hypercholesterolemia. Pastore et al. injected  these mice, 
maintained on high fat diet, intravenously with a HD-Ad vector expressing the 
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entire human ApoA-I gene (Pastore, 2004). As a result of such a treatment, they 
showed supraphysiological levels of expression of transgene and a reduction of 
lesion size. In sum, using ApoA-I transgene, these mice showed a reduction of the 
development of atherosclerosis in absence of a significant liver toxicity.  
The other animal model used in atherosclerosis studies is a mouse lacking the 
gene for LDLR (LDLR-/-) whose mutations, in humans, cause familial 
hypercholesterolemia. The LDLR-/- mice display a modestly elevated plasma 
cholesterol level, when maintained on a regular chow diet, and develop only a 
slow atherosclerosis. When these mice are fed on high fat diet, they show a strong 
increase in plasmatic levels of cholesterol as well as a rapid development of 
atherosclerotic lesion. Interestingly, the plasma lipoprotein profile resembles that 
of humans, with the cholesterol being confined mainly to the LDL fraction. Also 
this animal model was used in gene therapy. The systemical injection of a vector 
expressing the entire gene of human ApoA-I, in mice maintained on a high-
cholesterol diet for several weeks, leads to a small increase of plasma human 
ApoA-I, compared with control mice. Moreover, it is also possible to observe a 
delay in the atherosclerosis progression and a remodelling of the lesions to a more 
stable phenotype (Tangirala, 1999; Belalcazar, 2003). Obviously, the use of an 
HD-Ad vector permits a reduction in liver toxicity and a long-term hepatic ApoA-
I expression (until 24 weeks), that cannot be pointed out in the same animals 
treated with a FG-Ad vector. The LDLR-/- mice, fed with a diet containing 
cholesterol and coconut oil, were also treated with murine VLDLR. Even in these 
experiments, after a single intravenous injection, plasma total cholesterol shows a 
reduction. In particular, the lowering is most marked in the fraction IDL/LDL, 
suggesting that the treatment leads to a marked reduction in the atherogenic 
potential of plasma lipoproteins. Moreover, the aortic atherosclerosis is prevented 
in these animals (Kobayashi, 1996; Oka, 2001). Recently, LDLR-/- mice fed with 
high cholesterol diet were treated systemically with a HD-Ad vector expressing 
the monkey LDLR (Nomura, 2004). This treatment resulted more effective than 
that performed by using HD-Ad-VLDLR both in lowering plasma cholesterol and 
in the progression of aortic atherosclerosis lesions. This is possible because LDLR 
binds, with high affinity, both ApoE and ApoB-100 containing lipoproteins, 
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whereas VLDLR binds with lower affinity solely ApoE containing lipoproteins. 
This difference underlies the fact that VLDLR mediates the uptake of only IDL 
but not LDL, whereas LDLR mediates the uptake of both IDL and LDL. 
However, some animals display anti-LDLR antibodies, with an obviously 
premature return of hypercholesterolemia. These observations suggest that the 
immune response to the vector and transgene product plays an important role in 
curtailing the therapeutic response to the treatment.     
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MATERIALS AND METHODS 
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1 Production of Helper-dependent adenoviral vectors. 
 
Two HD-Ad vectors were used in the following studies. The first vector, HD-Ad-
LacZ, contains the expression cassette for β-galactosidase gene under the control 
of the MCMV promoter (Palmer, 2003), while the second vector, HD-Ad-ApoA-I, 
contains 10 kb of the human APOA-I gene, including the promoter region 
(Belalcazar, 2003). Rescue and amplification of the vectors were performed using 
the HV-Ad-NG163R-2 helper virus as described. Briefly, 60-mm 
dish of 116 cells at 80% confluency were transfected with 20 µg of PmeI-digested 
parental plasmid. Next day, the cells were infected with AdNG163R-2 at an m.o.i. 
of 1000 vp/cell. The vectors were amplified by serial coinfections of 60-mm 
dishes of 116 cells at 90% confluency with 10% of the crude lysate from the 
previous passage and HD-Ad-NG163R-2 at an m.o.i. of 200 vp/cell. After 3 
infection in 60 mm dish, one 150-mm dish of 116 cells at 90% confluency was 
coinfected with 10% of the crude serial passage 2 lysate and HD-Ad-NG163R-2 
at an m.o.i. of 200 vp/cell. Large-scale HD-Ad production was performed in 3 
liters of 116 cells (3–4x105 cells/ml) coinfected with 100% of the crude lysate 
from the 150-mm dish of serial passage 3 and HD-Ad-NG163R-2. 48 h later, 
coinfected cells were harvested and HD-Ad virions were purified by two step of 
CsCl ultracentrifugations and dialyzed against 10 mM Tris–HCl pH 8.0, 4% (v/v) 
sucrose at 4 °C. Vector concentration was determined by UV spectrophotometric 
analysis at 260 nm. The title of HD-Ad-LacZ was also determined by X-gal 
staining on 293 cells as described previously (Ng, 2002) and expressed as BFU. 
Helper virus contamination was checked by Southern blot analysis on DNA 
extracted from the vector prep. Briefly, viral DNA was digested with PstI 
restriction enzyme and the hybridization was carried out at 55°C using HD-Ad-
ITR probes; ECL plus was used as detection system. Helper virus was not 
detectable by Southern blot analysis and so the contamination can be considered 
<0,1%. 
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2 PEGylation of HD-Ad vectors. 
 
The protein content of each viral preparation was determined with Bio-Rad DC 
Protein assay reagents and bovine serum albumin was used as standard. In total, 
10 mg of monomethoxypoly(ethylene) glycol activated by succinimidyl succinate 
(SSPEG, mw 5000) was added for each microgram of protein present in each 
preparation. Conjugation reactions were performed at 25°C with gentle agitation. 
Reactions were stopped by addition of a 10-fold excess of L-lysine with respect to 
the amount of PEG added. Unreacted PEG, excess lysine, and reaction products 
were eliminated by buffer exchange over a second Econo-Pac 10DG disposable 
chromatography column, equilibrated with 100 mM potassium phosphate-
buffered saline (pH 7.4). A separate aliquot of virus was treated and processed in 
the absence of SSPEG in the same manner as the conjugated virus and served as 
the unPEGylated control. 
 
3 Characterization of PEGylated HD-Ad vectors.  
 
PEGylated and unPEGylated adenoviral vectors were characterized by capillary 
zone electrophoresis using a Beckman PACE 5000 system with an untreated 50 
µm(ID)x27 cm capillary. The temperature of the capillary was controlled at 22°C. 
A preliminary 2 min wash in 1 N NaOH followed by a 2-min wash in nanopure 
water and a third wash in running buffer (20 mM sodium phosphate, pH 7.0, 5 
mM sodium chloride) were performed prior to sample analysis. A voltage of 17 
kV was used for the separations and the detector signal at 214 nm was recorded 
and processed by the PACE station software package. 
 
4 Immunoturbidimetric assay. 
 
The expression of human ApoA-I was evaluated by immunoturbidimetric 
analysis. 293 and W20-17 cells were infected with 200 vp/cell of HD-Ad-ApoA-I 
and PEG-HD-Ad-ApoA-I. Non infected 293 and W20-17 cells were used as 
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negative controls. Fourty-eight hours after the infection, the medium was 
collected and a detergent solution was added at 37°C for 2 min. The absorbance at 
610 nm was read (Abs1) and goat serum containing anti-human ApoA-I was 
added. The absorbance at 610 nm was read again (Abs2) and the concentration of 
human ApoA-I was calculated as ∆Abs=Abs2-Abs1 on the calibration curve. 
Human serum with high and low concentration of ApoA-I was used as a positive 
control of the assay. 
 
5 Animal studies. 
 
MyD88-/- mice were provided by S. Akira (Department of Host Defense, Research 
Institute for Microbial Diseases, Osaka University); TLR2-/-, LDLR-/- and 
C57BL/6 mice were purchased from Jackson laboratories. Food and water were 
provided ad libitum.  All experimental procedures were conducted in accordance 
with institutional guidelines for animal care and use.  
The mice used in the toxicity experiment were female 8-12 weeks old. Eight 
weeks LDL receptor-deficient (LDLR-/-) female mice, on a C57BL/6 background, 
were fed on a diet supplemented with 0.2% (wt/wt) cholesterol and 10% coconut 
oil (vol/wt) for 4 weeks. HD-Ad was diluted in sterile PBS, prewarmed at 37°C, 
and injected into tail vein. The injections were performed in a total volume of 200 
µl. Mice were anesthetized with Avertine before collecting blood from the 
retroorbital plexus. For cytokines analyses, blood was collected at 6 h and, for 
ALT determination, 3, 7 and 14 days postinjection. To analyse triglycerides, total 
cholesterol, LDL-C and HDL-C, blood was collected at 1, 2, 4, 8 and 12 weeks 
after vector administration from 12 hours fasting mice. Serum was frozen 
immediately and stored at −20°C until analyses. For β-galactosidase staining, 
mice were killed 48 h postinjection. Upon sacrifice, the liver was harvested and 
kept on dry ice or at −80°C until analyses. To analyse atherosclerotic lesion, mice 
were sacrificed 12 weeks after the treatment and aortas were taken. 
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6 Evaluation of toxicity. 
 
Mouse IL-6 and MCP-1 was assayed by using the BD cytokine multiplex bead 
array system and analyzed using a BD FACSArray instrument, according to 
manufacturer’s instructions. Briefly, beads against these cytokines were mixed to 
10 µl of serum and incubated at room temperature for 1 hour. PE detection 
reagent was added and incubated again in the same conditions. Samples were run 
at FACSArray and the data were analysed by FACSArray System Software. 
IL-12p40 was assayed by Immunoassay kit according to the manufacturer’s 
instruction. 
Mouse ALT levels were measured enzymatically on 100 µl of serum by using 
Vitros 250 Analyser, based on  spectrophotometric dry chemistry. 
 
 
7 X-Gal staining and β-Gal enzyme assay. 
 
For X-gal staining, liver samples from each animal were embedded in Tissue-Tek 
O.C.T. compound and frozen until used for sectioning. Frozen sections (8 µm) 
were prepared on a refrigerated microtome and fixed with 1.25% glutaraldehyde 
at 4°C for 10 minutes. Slides were rinsed twice with PBS and immersed in X-gal 
(5-bromo-4-chloro-3-indolyl-β-D-galactosidase) solution.  
For β-galactosidase determination, total proteins were extracted from the liver and 
the enzyme activity was determined using β-Galactosidase Enzyme Assay System 
with Reporter Lysis Buffer. Protein content was determined with the Micro BCA 
protein assay reagent kit using BSA as standard. 
 
8 Lipids measurement. 
 
Mouse triglycerides, total cholesterol, HDL-C and LDL-C levels were  measured 
enzymatically on 100 µl of serum by using Vitros 250 Analyser, based on  
spectrophotometric dry chemistry. 
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9 Dissections of aortas and quantization of atherosclerotic lesions. 
 
Twelve weeks after treatment, mice were sacrificed and aortas, from heart to iliac 
branching, were dissected out. Briefly, mice were euthanized and the viscera were 
cut out. Then, aortas were dissected out and fat and leftover tissues carefully cut 
out until aortas were clean, to proceed, thereafter, with their opening. To quantize 
the intimal fat, aortas were fixed in 4% Buffered Formal Saline solution and 
stained with Oil Red O.  Images were acquired using Sigma Scan Pro and the fat  
amount were quantified with NIS elements program. 
 
 
10 Statistical analysis.  
 
Results were analysed using two-way (treatment-time) ANOVA with repeated 
measures, followed by Fischer’s post-hoc comparison when required. A 
significance level of p<0,005 was accepted as statistically significant. All 
measures are expressed as mean ± standard error of the mean (S.E.M.). All 
statistical analyses were performed with StatView software (version 567 5.0.1.0; 
SAS Institute, Cary, NC). 
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1 Production and characterization of HD-Ad vectors. 
 
The HD-Ad plasmid expressing LacZ, p∆28E4LacZ, was constructed at Baylor 
College of Medicine in Houston by Ng, as follows: the 3.6-kb PshAI fragment 
was replacing from p∆28E4 with the Klenow-treated 4.7-kb XbaI–BglII fragment, 
containing the MCMV–LacZ expression cassette from pCA35. To a large scale 
production, the 29.3-kb HD-Ad, HD-∆28-E4-LacZ, was rescued following PmeI 
digestion of p∆28E4LacZ and trasfected in 116Cre4 cells and 24 hours after the 
transfection, the cells were infected with the helper virus, AdNG163R-2, to permit 
the assembly of virions. Several passages of infections of adherent 116Cre4 cells 
with the lysates of 60mm dishes and AdNG163R-2 were carried out until the 
coinfection of 2 liters of 116Cre4 cells growing in suspension. Forty-eight hours 
post coinfection, we purified HD-∆28-E4-LacZ by ultracentrifugation in 
continuous CsCl gradient (Fig. 14 A). Spectrophotometric analysis revealed that 
we obtained a total yield of 1x1013 vp (viral particles) corresponding to about 
25000 vp/cell. To analyze the ratio between the infection particles and the viral 
particles expressing LacZ, an X-gal staining was performed on 293 cells: the HD-
∆28-E4-LacZ was 8x1011 BFU (blue forming units)/ml, for a ratio vp:BFU of 
about 10:1. To use this HD-∆28-E4-LacZ  for in vivo toxicity studies, we had also 
determined the helper virus contamination through Southern blot analysis of viral 
DNA using the ITR probe hybridized to PstI-digested DNA. As shown in figure 
14 B (Fig. 14 B) the helper virus contamination was undetectable and this was 
consistent with a contamination of loss than 0,1%. Indeed, HD-∆28-E4-LacZ had 
the some structure of the parental plasmid, p∆28E4LacZ (line 1 and 3 of figure 14 
B). At University of Texas in Austin, a part of the vector HD∆28E4LacZ had 
undergone the PEGylation reaction, that, based upon previous experience with 
PEGylation of viral vectors (Croyle, 2005), was carried out for 2 hours at room 
temperature. Changes in the surface properties of the viral capsid, due to the bind 
with PEG, was monitored by capillary electrophoresis (Fig. 15). Unmodified HD-
Ad, which has treated according to PEGylation protocol but without adding PEG,  
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Figure 14. HD-∆28-E4-LacZ purification and helper virus 
contamination. 
   
(A) HD-D28-E4-LacZ after ultracentrifugation in continuous CsCl gradient. (B) 
Southern blot analysis of plasmid and viral DNA to verify helper virus 
contamination. Plasmid and viral vector were digested with PstI and fractionated 
on a 1% agarose gel. Southern blot analysis was performed using a probe 
hybridized on ITRs. Lane 1,  HD-D28-E4-LacZ; lane 2, AdNG163R-2; lane 3, 
p∆28E4LacZ.  
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Figure 15. Capillary electrophorogram. 
Representative capillary electropherograms of (a) HD-D28-E4-LacZ (b) 
unmodified HD-D28-E4-LacZ (c) HD-D28-E4-LacZ after the ultacentrifugation, 
before PEGylation. Samples were diluted 1:2 with sample buffer (20 mM sodium 
phosphate buffer, pH 7.0, 5 mM sodium chloride). Capillary length was 27 cm. 
Virus was detected at 214 nm. AU, absorbance units. 
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had a peak at about 22 minutes. This peak was superimposable to that obtained 
with the HD-Ad collected after the CsCl ultracentrifugation. Indeed, the PEG-HD-
Ad vector was detected as a single peak at 10 minutes and the unmodified vector 
was absent from PEGylated preparation, indicating that all viral particles had 
reacted with PEG.  
The HD-Ad plasmid containing the entire human ApoA-I gene, p∆21ApoA-I, was 
obtained at Baylor College of Medicine in Houston by Belalcazar, as follows: 10 
kb of the human ApoA-I gene, including the promoter region, was inserted into 
the pLPBL1 plasmid and subcloned into the unique AscI site of the p∆21 plasmid,  
that contained the inverted terminal repeats, the packaging signals of adenovirus 
type 5 and DNA stuffer from the human HPRTB gene and the cosmid C346. The 
corresponding vector, HD-Ad-ApoA-I, was obtained according the protocol used 
for the HD-∆28-E4-LacZ. Also for HD-Ad-ApoA-I, the spectrophotometric 
analysis was made: the concentration of vector resulted been 7x1012 vp/ml. To 
assay helper virus and PEGylation reaction, the Southern blot and capillary 
electrophoresis were carried out but obviously the data are not show because the 
probe used in Southern blot hybridized on ITRs, which are the some for all 
vectors, and the peaks obtained from capillary electrophoresis are very similar to 
the previous. However, to evaluate the levels of expression of human ApoA-I, 293 
and W20-17 cells (a mouse cell line) were infected with HD-Ad-ApoA-I modified 
and unmodified and the human ApoA-I secreted in the medium was measured 
with an immunoturbidimetric assay. As shown in figure 16 (Fig. 16) both 293 and 
W20-17 cells had very low basal levels of secreted ApoA-I (17 ± 3,5ng/µl and 13 
± 0,3 ng/µl, respectively). The infection with HD-Ad-ApoA-I or PEG-HD-Ad-
ApoA-I led to an increase in the secretion of the protein of about 4 folds in 293 
(77 ± 28 ng/µl) and 2 in W20-17 cells (27 ± 6 ng/µl), when they were infected 
with unmodified vector, or about 3 folds (54 ± 8 ng/µl) and 2,5 (32 ± 6 ng/µl) in 
293 and W20-17 respectively. The lower secretion of ApoA-I in W20-17 cells 
than in 293 was probably due to a lesser infectivity of these cells. Indeed, there 
were no significant differences in the secretion of ApoA-I when the cells were 
treated with HD-Ad or PEG-HD-Ad vector. This data confirms the functionality  
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Figure 16. Immunoturbidimetric assay.  
 
293 and W20-17 cells were infected with HD-Ad-ApoA-I and PEG-HD-Ad-
ApoA-I and the secreted protein were measured. Non infected 293 and W20-17 
cells were used as negative controls. The infection with the vectors led to an 
significant increase in the secretion of human ApoA-I in both cells lines compared 
with uninfected cells.   
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of both vectors and that the PEGylation reaction do not influence the expression 
of transgene. In short these vectors can be used for in vivo studies. 
 
2 Role of MyD88 in the acute inflammatory response triggered by         
systemic HD-Ad administration. 
 
To investigate the role of MyD88 in Ad acute toxicity, MyD88-/- mice in C57BL/6 
background (N=5) were injected with 1x1013 vp/kg of HD-Ad vector expressing 
LacZ driven by the ubiquitous CMV promoter (HD-Ad-LacZ). Blood samples 
were collected 6 hours after the injection for platelets, AST, ALT and cytokine 
(IL-6 and IL-12) determinations and the results from MyD88-/- mice were 
compared to those generated in C57BL/6 (WT) controls (N=5) injected under the 
same identical conditions. No difference in the levels of both AST and ALT were 
observed between the two groups of mice (data not shown). Also, similar 
reduction in platelet counts was noted among the two mouse strains (data not 
shown).  However, MyD88-/- mice showed a drastic (more than 80%) reduction in 
IL-6, (1,200 pg/ml ± 200 in WT treated mice vs 200 pg/ml ± 59 in MyD88-/-
treated mice; p<0,002) (Fig. 17 A), and an approximately 60% of reduction in IL-
12 (1065 pg/ml ± 80 in WT-treated mice vs 404 pg/ml ± 180 in MyD88-/- treated 
mice; p<0,03) (Fig. 17 B). Although less prominent, reduction in MCP-1 levels 
was also observed (Fig. 17 C). In the same mice sampled for cytokine levels, liver 
samples collected on day 3 post-injection were assayed for β-galactosidase 
activity to determine transduction efficiency and no significant difference in 
transduction efficiency were noted between the MyD88-/- and control mice (Fig. 
18). Therefore, the reduction in cytokines levels is not accompanied to a reduction 
in efficiency liver gene transfer. These results show that MyD88 is a major player 
in the activation of the proinflammatory acute response following systemic Ad 
vector administration. Being a crucial component of the downstream activation 
pathway of several TLRs, and considering previous studies, showing that TLR9 
has a relatively minor role in Ad acute toxicity, we hypothesized that other TLRs 
are likely to be involved through MyD88 activation in the acute inflammatory 
response triggered by Ad vectors. 
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Figure 17. MyD88 role in the innate response to HD-Ad. 
 
MyD88-/-mice in C57BL/6 background were injected with 1x1013 vp/kg HD-Ad-
LacZ. C57BL/6 mice were injected with the same dose as a control. Six hours 
after the injection plasma samples were collected and cytokines levels were 
assayed. (A) IL-6 was assayed by FACSARRAY. (B) IL-12p40 was assayed by 
ELISA. (C) MCP-1 was assayed by FACSARRAY as described in Material and 
Methods. * p<0,05; ** p<0,03 
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Figure 18. Hepatocyte transduction following systemic injection of 
HD-Ad-LacZ in C57BL/6 and MyD88-/- mice.  
 
MyD88-/- and C57BL/6 mice were injected with 1x1013 vp/kg of HD-Ad-LacZ. 
C57BL/6 mice were injected with the same dose as control. 72 hours after vector 
administration, livers were collected for analysis. Another cohort of mice were 
injected with PBS as negative control. (A) X-Gal staining of liver from C57BL/6 
and MyD88-/- mice following administration of the vector. PBS was used as 
negative control. (B) β-galactosidase expression from liver from C57BL/6 and 
MyD88-/- mice. 
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3 TLR2 deficiency attenuates the innate immune response to HD-     
Ad vectors in vivo. 
 
Being a crucial component of the downstream activation pathway of several 
TLRs, and considering previous studies, showing that TLR9 has a relatively 
minor role in Ad acute toxicity, we hypothesized that other TLRs are likely to be 
involved through MyD88 activation in the acute inflammatory response triggered 
by Ad vectors. 
TLR(s) expressed on the plasma membrane would be good candidates and 
therefore we decided to start  investigating the role of TLR2 which is known to 
localize on the plasma membrane. To this end, we analyzed the cytokine 
activation profile in TLR2-/- mice, in C57BL/6 background, administered with 
different doses of HD-Ad as compared to a control group (C57BL/6 mice) 
injected with the same vector at the same doses. TLR2-/- mice (N=5 per treatment 
group) were injected with either 5x1012 or 1x1013 vp/kg of HD-Ad-LacZ. TLR2-/- 
mice were found to have a less severe increase of proinflammatory cytokines 
compared to the control group (Fig. 19). Blood samples for cytokine analyses 
were collected at 6 hours and liver samples for quantitative β-galactosidase 
activity at 72 hours post-injection. At the dose of  1x1013 vp/kg, the IL-6, IL-12 
and MCP-1 levels were found to be significantly different between TLR2-/- (600 ± 
150 pg/ml, 452 ± 198 pg/ml and1 750 ± 328 pg/ml, respectively) and C57BL/6 
mice (1350 ± 108 pg/ml, 998 ± 89 pg/ml and 3500 ± 553 pg/ml, respectively). 
Also at the lower dose of 5x1012 vp/kg, IL-6, IL-12 and MCP-I were assayed, and 
consistently with previous data, IL-6 levels were significantly reduced in TLR2-/- 
mice (270 ± 123 pg/ml) as compared with C57BL/6 mice (550 ± 118 pg/ml) 
(p<0.03). Similarly, IL-12 levels in TLR2-/- mice were 260 ± 103 pg/ml while in 
C57BL/6 mice were 554 ± 102 pg/ml (p<0.05). The hepatocyte transduction was 
essentially the same among the treated groups (Fig. 20).  
Taken together, these data show that TLR2 is an important early sensing receptor 
in the activation of the acute inflammatory response to HD-Ad vectors in vivo.  
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Figure 19. TLR2 deficiency attenuates innate immune response to 
HD-Ad in vivo. 
 
Two groups of TLR2-/- were injected with two different doses (5x1012 vp/kg and 
1x1013 vp/Kg) of HD-Ad-LacZ. C57BL/6 mice were injected with the same doses 
as control. Six hours after the injection plasma samples were collected and 
cytokine levels were assayed. IL-6 (A) and MCP-1 (C) levels were measured by 
FACSARRAY. IL-12 (B) levels were measured by ELISA.**, p<0,03; *, p<0,05 
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Figure 20. Hepatocyte transduction following systemic injection of 
HD-Ad-LacZ in C57BL/6 and TLR2-/- mice. 
 
TLR2-/- mice were injected with either 5x1012 and 1x1013 vp/kg of HD-Ad-LacZ. 
C57BL/6 mice were injected with the same doses as control. 72 hours after vector 
administration livers were collected and homogenized for β-galactosidase 
expression assay. Another cohort of mice were injected with PBS as negative 
control. 
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4 PEGylation masks the interaction between HD-Ad and the  
TLR2. 
 
Several groups have demonstrated that systemic administration of PEGylated Ad 
into mice resulted in a 50% to 70% reduction in serum IL-6 compared to 
unPEGylated vector without compromising hepatic transduction efficiency. The 
mechanism responsible for this effect is unclear and we hypothesized that the 
PEG could mask the vector from TLRs activation. We have therefore investigated 
the activation of the proinflammatory cytokines (IL-6, IL-12) in MyD88, TLR9 
and TLR2 knock-outs, and C57BL/6 control mice at 6 hours after the injection of 
1x1013 vp/kg of either PEGylated or unPEGylated HD-Ad-LacZ. As previously 
reported, there were significant cytokine reductions of 40-45% between 
PEGylated and unPEG HD-Ad in C57BL/6 mice. Indeed, IL-6 value was 550 ± 
78 pg/ml in the group of mice injected with HD-Ad-LacZ while it was 250 ± 123 
pg/ml in mice treated with PEG-HD-Ad-LacZ (p<0.05) (Fig. 21 A). Also IL-12 
value was different among the group of mice injected with HD-Ad-LacZ and that 
treated with PEG-HD-Ad-LacZ (554 ± 102 pg/ml vs 226 ± 156 pg/ml, 
respectively; p<0.05) (Fig. 21 B). However, no significant differences in both IL-
6 and IL-12 were noted between MyD88-/-, TLR9-/- and TLR2-/- mice (Fig. 21 A, 
B). Indeed, in MyD88-/- mice, IL-6 value was 148 ± 39 pg/ml in mice injected 
with HD-Ad-LacZ versus 159 ± 43 pg/ml in PEG-HD-Ad-LacZ receiving group 
(Fig. 21 A), instead IL-12 value was 128 ± 42 pg/ml in the animal treated with 
HD-Ad-LacZ versus 96 ± 40 pg/ml in the group of mice injected with PEG-HD-
Ad-LacZ (Fig. 21 B). The same difference, in IL-6 and IL-12 levels, were showed 
in TLR9 KO mice: IL-6 value was 387 ± 59 pg/ml vs 298 ± 83 pg/ml and IL-12 
value was 322 ± 68 pg/ml vs 284 ± 21 pg/ml, respectively in mice administrated 
with HD-Ad-LacZ and PEG-HD-Ad-LacZ vectors (Fig. 21 B).  
Being the TLR9 expressed in the endosome and activated by esogenous DNA, it 
is not expected to be affected by vector PEGylation.  The IL-6 levels, in TLR2-/- 
mice, were comparable between mice injected with HD-Ad-LacZ and PEG-HD-
Ad-LacZ (Fig. 21 A). Also IL-12 values were not significantly different between  
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HD-Ad-LacZ and PEG-HD-Ad-LacZ treated mice (Fig. 21 B).  The β-
galactisidase assay on liver samples showed no significant differences in 
hepatocytes transduction efficiency (data not shown).   
Taken together these data show the lack of protective effect of PEG on the 
activation of the pro-inflammatory cytokines in MyD88-/- and TLR2-/- mice 
consistently with the hypothesis that PEG prevents adenoviral vector from 
activation of TLRs.  The residual cytokine response observed suggests that other 
pathways independent from the TLR are activated by systemic Ad administration.   
 
5 Toxicity of HD-Ad-ApoA-I and PEG-HD-Ad-ApoA-I in a mouse   
model of atherosclerosis. 
 
As above mentioned, we have shown that PEG molecules can hide the viral capsid 
proteins to the immune system cells. In particular, the ability of PEG to mask the 
interaction of vector with TLR2 leads to a mitigating proinflammatory cytokine 
activation. This important observation needs to be corroborate in a model of 
pathology, to eventually proceed with clinical studies. To this aim, we tested 
PEGylated and non PEGylated HD-Ad vector expressing ApoA-I in a mouse 
model of atherosclerosis. Eight weeks old LDLR-/- mice (N=5) were fed on high 
cholesterol diet for 4 weeks and then injected systemically with 1x1013 vp/kg of 
HD-Ad-ApoA-I or PEG-HD-Ad-ApoA-I. Control animals (N=5) were treated 
with an equal volume of PBS. At different time points (0, 6, 24 and 72 hours), 
blood samples were collected to analyse the serum levels of IL-6, the main marker 
of inflammation. At 0 hours, as expected, there were no differences among 
groups, but after the administration of the vectors, an increase in proinflammatory 
cytokine was observed (Fig. 22). In particular, mice treated with HD-Ad-ApoA-I 
showed  a strong increase of serum levels of IL-6 compared to animals receiving 
PEG-HD-Ad-ApoA-I (1300 ± 300 pg/ml and 400 ± 61 pg/ml, respectively; p = 
0,001) (Fig. 22 A). However, in both treated animals groups, IL-6 levels returned 
at basal levels starting from 24 hours.   
Within the same groups of animals, we measured alanine transaminase (ALT), as 
index of liver vectors-induced toxicity. Blood samples were collected for ALT 
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Figure 21. PEG protects viral vector from interaction with TLRs 
family. 
 
MyD88-/-, TLR9-/- and TLR2-/- were injected with 1x1013vp/kg, C57BL/6 mice 
were used as controls. Blood samples were collected 6 hours after vector 
administration and cytokines analysis was performed. (A) IL-6 was assayed by 
FACSARRAY. (B) IL-12p40 was assayed by ELISA. **, p<0,03, *, p<0,05. 
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determination at 0, 3, 7, 14 days after the injection: as for IL-6, at 0 day, there 
were no differences among the groups (Fig. 22 B). Differently to 
proinflammatory cytokines, at different time points (3, 7 and 14 days), ALT 
values did not undergo changes from baseline, in animals treated with both 
PEGylated and non PEGylated vector. As shown in previous works (Croyle, 
2005), this data confirms that HD-Ad-vectors have a very low liver toxicity, 
which is independent from capsid modification.  
 
6   HD-Ad-ApoA-I, but no PEG-HD-Ad-ApoA-I, induces effects in 
blood lipidic pattern. 
 
To evaluate the effects of overexpression of human ApoA-I on the cholesterol 
metabolism, 8 weeks old LDLR-/- mice (N=5), maintained on an atherogenic diet 
for 4 weeks, were injected into tail vein with 1x1013 vp/kg of HD-Ad-ApoA-I or 
PEG-HD-Ad-ApoA-I. Another group of animals (N=5) was used as negative 
control and received, systemically, an equal volume of PBS. Triglycerides, total 
cholesterol, LDL-cholesterol (LDL-C) and HDL-cholesterol (HDL-C) were 
measured at different weeks (1, 2, 4, 8 and 12 weeks) after the administration of 
the vectors. Basal plasma triglycerides were 97 ± 5 mg/dL in control mice, 88,5 ± 
3 mg/dL in HD-Ad-ApoA-I treated mice and 97,3 ± 2 mg/dL in mice receiving 
PEG-HD-Ad-ApoA-I (Fig. 23 A). These levels were not modified by the 
expression of human ApoA-I. Indeed, during weeks, there were no differences 
among groups, treated and not, compared with triglycerides value at 0 time.  
About total cholesterol, its basal levels were 520 ± 60 mg/dL, 536 ± 50 mg/dL, 
550 ± 100 mg/dL in PBS, HD-AD-ApoA-I and PEG-HD-Ad-ApoA-I injected 
mice, respectively (Fig. 23 B). After a single administration of HD-Ad-ApoA-I, 
an increase in total cholesterol was observed. This value reached a peak at 4 
weeks, showing a considerable difference from control mice (730 ± 30 mg/dL vs 
450 ± 80 mg/ dL; p = 0,006). Total cholesterol levels persisted at high values until 
the end of  the experiment at 12 weeks. Instead, the administration of PEG-HD-
Ad-ApoA-I did not induce any effects on the total cholesterol levels, which 
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Figure 22. HD-Ad-ApoA-I and PEG-HD-Ad-ApoA-I toxicity. 
 
LDLR-/- mice were injected systemically with 1x1013 vp/kg of HD-Ad-ApoA-I 
and PEG-HD-Ad-ApoA-I. Mice treated with a same volume of PBS were used as 
control. At 6, 24 and 72 hours after the injection, blood samples were collected. 
IL-6 levels (A) were analysed by FACSARRAY. At 3, 7 and 14 days after 
treatment, ALT levels (B) were assayed on blood samples.  
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remained at values comparable to baseline also at 4 weeks (350 ± 77 mg/dL), 
when cholesterol in HD-Ad-ApoA-I injected mice reached the highest levels.    
To evaluate the influence of ApoA-I on reverse transport of cholesterol, we also 
analysed serum levels of LDL-C and HDL-C. The basal LDL-C level was 
comparable among the 3 groups (389 ± 55mg/dL, 399 ± 57 mg/dL and 420 ± 100 
mg/dL in PBS, HD-Ad-ApoA-I and PEG-HD-Ad-ApoA-I groups, respectively) 
(Fig. 23 C). In HD-Ad-ApoA-I treated mice, LDL-C showed an evident decline 
starting from the second week of vector administration until the last one. In 
particular, at 4 weeks, when the total cholesterol levels reached the highest 
increase, we observed very low concentration of LDL-C compared to that of 
control mice (148 ± 16 mg/dL vs 399 ± 57 mg/dL). In PEG-HD-Ad-ApoA-I 
injected mice, the trend of LDL-C was the same than that shown by control mice, 
throughout the experiment. Also for HDL-C,  the basal levels were the same 
among the 3 groups (114 ± 6 mg/dL, 118 ± 5 mg/dL and 109 ± 8 mg/dL in PBS, 
HD-Ad-ApoA-I and PEG-HD-Ad-ApoA-I groups, respectively) but, starting from 
the second week after the injection of HD-Ad-ApoA-I, HDL-C values increased, 
while LDL-C declined (Fig. 23 D). In this group of animals, HDL-C was 
significantly higher then that in control mice (p<0,0001) until the 12 weeks, 
reaching plateau already at 4 weeks. Instead, PEG-HD-Ad-ApoA-I treated mice 
showed, also in HDL-C, the same trend of untreated animals.  
 
7 HD-Ad-ApoA-I treatment prevents aortic atherosclerotic    
development. 
 
As demonstrated  in our experiments, mentioned above, LDLR-/- mice, injected 
with HD-Ad-ApoA-I, show an improvement in reverse transport of cholesterol, 
associated with higher levels of HDL-C and consequently lower levels of LDL-C 
than untreated mice. To check if these changes in the lipidic metabolism have an 
effect on the atherosclerotic lesion development, we sacrificed animals 12 weeks 
after vectors injection and dissected out the aortas, from heart to iliac branching. 
At a macroscopic analysis, fat deposits were observed, as expected,  in the intimal  
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Figure 23. HD-Ad-ApoA-I treatment have a positive effect on 
metabolism of cholesterol. 
 
LDLR-/- mice were injected systemically with 1x1013 vp/kg of HD-Ad-ApoA-I 
and PEG-HD-Ad-ApoA-I. Mice treated with a same volume of PBS were used as 
control. 1, 2, 4, 8 and 12 weeks after the treatment, blood samples were collected. 
Triglycerides (A), total cholesterol (B), LDL-C (C) and HDL-C (D)  levels were 
analysed.  
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layer of brachiocephalic trunk, left common carotid artery and left subclavian 
artery, the branches gives off aortic arch (Fig. 24). Moreover, other lesions were 
looked through abdominal aorta, upstream kidney bifurcation. A thorough 
analysis showed  more consistent deposits in mice treated with PBS and PEG-HD-
Ad-ApoA-I than that in mice injected with HD-Ad-ApoA-I. Indeed, the first two 
groups of animals had a greater amount of fats at level of aortic arch than the last 
group of mice and at abdominal aorta level, in mice administrated with PBS and 
PEG-HD-Ad-ApoA-I, it was possible observed an occlusion of the artery, 
associated with a dilatation of the vessel in the point in which fats were deposited. 
This obstruction  was not reported in mice receiving HD-Ad-ApoA-I vector. To 
quantify the atherosclerotic lesion, directly correlated with fat deposits, an O-Red-
Oil staining was carried out on the aortas, opening and cleaning from external fat 
and leftover tissues. The density of fats, staining in red, was quantified on the area 
of whole aorta and it was 2 ± 0,53, 0,65 ± 0,3, 1,9 ± 0,48  in mice treated with 
PBS, HD-Ad-ApoA-I and PEG-HD-Ad-ApoA-I respectively (Fig. 25). The 
reduction in lesion area was significant in animals injected with HD-Ad-ApoA-I 
compared with the mice receiving PBS and PEG-HD-Ad-ApoA-I (p<0,0001). All 
the data obtained in mice treated with HD-Ad-ApoA-I, but not with PEG-HD-Ad-
ApoA-I, are in accordance with our observations on cholesterol metabolism and 
correlate  with previously experiments (Pastore, 2004) in which an improvement 
in reverse transport of cholesterol is associated with a decrease in aortic 
atherosclerotic development.  
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Figure 24. HD-Ad-ApoA-I treatment prevents fat deposits 
accumulation.   
 
LDLR-/- mice were injected systemically with 1x1013 vp/kg of HD-Ad-ApoA-I 
and PEG-HD-Ad-ApoA-I. Mice treated with a same volume of PBS were used as 
control. Twelve weeks after the injection, mice were sacrificed and aorta were 
dissected. Panels show fat deposits in aortic arch and abdominal aorta in treated 
and untreated mice. 
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Figure 25. HD-Ad-ApoA-I treatment leads to a decrease in aortic 
atherosclerotic lesions. 
 
LDLR-/- mice were injected systemically with 1x1013 vp/kg of HD-Ad-ApoA-I 
and PEG-HD-Ad-ApoA-I. Mice treated with a same volume of PBS were used as 
control. Twelve weeks after the injection, mice were sacrificed and aortas were 
dissected and stained with O-Red-Oil to identify fats deposits. Red intensity was 
measured on the area of whole aorta as index of atherosclerotic lesions. 
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DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 64 - 
Adenovirus mediated gene therapy holds significant potential especially for 
applications requiring high levels of target tissue transduction and long term 
expression of transgene. Nevertheless, the clinical translation of adenoviral gene 
replacement therapy for genetic disease is lagged by vector associated toxicity. 
Advances in vector production have led to the development of Helper-Dependent 
adenoviral vectors (HD-Ad) which are characterized by the deletion of all viral 
coding genes. HD-Ad significantly reduces chronic toxicity which, on the 
contrary, is strongly induced, in both small and large animal models, by systemic 
administration of early generation adenoviral vectors. However, even using HD-
Ad vectors, innate immune response to adenoviral capsid proteins persists as well 
as the adaptive immune response to transgene. Together, these two host responses 
lead to a decrease in the effectiveness of therapeutic index for any particular 
treatment. Several  studies have been carried out in order to reduce the innate 
immune response to HD-Ad vectors using different approaches such as 
hydrodynamic injection in mice (Brunetti-Pierri, 2005), balloon occlusion 
catheter-based method in non human primates (Brunetti-Pierri, 2007) and 
PEGylation of vectors, whose administration has been performed in mice, in 
association or not with immunosuppressive drugs (Croyle, 2005; De Geest, 2005). 
Nevertheless, the molecular pathways involved in the early phase of immune 
response to adenoviral vectors, are only partially understood.  
Therefore, in the first part of this study, we focused our attention in the 
elucidation of this topic. Previous studies showed that TLR9 (Cerullo, 2007), 
residing in the endosomal compartment of cells, can be activated by foreign DNA, 
including the adenoviral genome. The activation of TLR9 leads to an increase in 
serum levels of several cytokines, suggesting its involvement in the activation of 
the proinflammatory cytokines occurring after intravenous administration of HD-
Ad vectors. Although its significance, TLR9 does not play an important role in the 
first events involved in innate immune response to adenovirus, owing to its 
intracellular localization (Cerullo, 2007). This let hypothesize that other TLRs are 
involved in the host response. To verify this, we first characterized the role of 
MyD88 in the pathogenesis of the innate immune response that contributes to the 
in vivo HD-Ad toxic reaction following systemic administration. Moreover, we 
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also identified TLR2 as a major player of the acute inflammatory response. 
Indeed, PEGylation may mask the interaction between HD-Ad and TLR2, thus 
explaining a mechanism by which the PEG molecule can protect against the Ad-
mediated acute cytokine response.  
Regarding to the first point, we clearly showed that MyD88 knockout mice 
exhibit a 50-70% reduction of pro-inflammatory cytokines production when 
challenged systemically with high dose of HD-Ad. Since MyD88 is considered a 
key downstream component in the activation pathways of several TLRs, we have 
then decided to investigate the role of TLRs expressing on the plasma membrane. 
In particular, we have studied TLR2 which is known to function as a pattern 
recognition receptor for several microbial agents, including viruses, and is widely 
expressed from a variety of cell type, including hepatocytes and Kupffer cells. 
Moreover, TLR2 molecular pathway converges at activation of MyD88 signaling. 
As for MyD88-/- mice, TLR2-/- mice, injected with two different doses of HD-Ad 
vector, have shown, in both dosages, a decrease in proinflammatory cytokines. 
This drop in the level of cytokines, however, does not depend by a reduced 
hepatocytes transduction since this last phenomenon occurs at the same extent 
both in mutant and in wild type mice (C57BL/6). These data highlight an 
important role for TLR2 as an “early sensor” receptor implied in the activation of 
innate immune response to HD-Ad vectors. However, both MyD88 and TLR2 
knockout mice have not shown a complete abrogation of the toxic response, thus 
suggesting that other pathways are also involved in the activation of the pro-
inflammatory cytokine cascade. 
To strengthen the involvement of TLR2 in innate immune response to adenoviral 
vectors and clarify the mechanism involved in the reduction of toxicity of PEG-
HD-Ad, previously shown in several studies, we have treated TLR2-/- mice with a 
PEGylated vector. TLR2-/- mice exhibited a decrease in the proinflammaroty 
cytokines, compared to control C57BL/6 animals, providing evidence that PEG 
molecule could mask the viral capsid from the interaction with TLR2. Further 
experiments are necessary to elucidate whether a direct interaction between TLR2 
and viral capsid proteins occurs. Moreover, it remains to be elucidated whether 
other TLRs are engaged in the response to HD-Ad capsid. However, these 
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findings significantly contribute to dissect the molecular pathways involved in the 
innate response to HD-Ad and offer further target molecules for modulating the 
innate response, hence increasing the safety profile of HD-Ad vectors. Given that 
many players are involved in the acute toxic reaction to Ad vectors, blocking only 
one component of this network is unlikely to be beneficial. Therefore, 
combinatorial therapies to decrease toxicity could be required to increase the 
maximal tolerated dose and improve the therapeutic window of the therapeutical 
vector.  
Previous studies on toxicity induced by PEG-HD-Ad have been carried out 
exclusively on C57BL/6 mouse strain, evaluating the effect of the vector injection 
within 3 days after administration. Moreover, only one transgene (LacZ) has been 
used in the different studies performed to evaluate the toxicity of HD-Ad. This 
could turn out as a limitation, not allowing to point out if PEGylation reaction can 
influence the expression of other transgenes. Therefore, in the second part of this 
study, we aimed to check whether the use of PEG-HD-Ad vectors can be applied 
also to pathological animal models. For this reason, we have used a mouse model 
of atherosclerosis (LDLR-/- mice) which show increased basal levels of LDL-C 
and a development of atherosclerotic lesion, under a regimen of high cholesterol 
diet. A previous work on this animal model showed a correction of the 
pathological phenotype after the injection of HD-Ad-ApoA-I (Belalcazar, 2003). 
In this study, the retard in atherosclerosis progression and remodeling of the 
lesions was due to the overexpression of ApoA-I and the consequent increase in 
reverse transport of cholesterol. In our study, we treated LDLR-/- mice with high 
doses of HD-Ad-ApoA-I or PEG-HD-Ad-ApoA-I vector and followed, for 12 
weeks, the changes in the metabolism of cholesterol, in particular, in the levels of 
triglycerides, total cholesterol, LDL-C and HDL-C. As a first parameter of 
investigation, we measured the toxicity of vectors: as in C57BL/6 mice, the 
PEGylation of vector induced a lower increase in proinflammatory cytokines, 
compared to mice administered with HD-Ad vector. This data also indicates, for 
the first time, that the low toxicity due to PEG is independent from transgene used 
in the therapy. Even if PEG-HD-Ad-ApoA-I displayed low levels of IL-6, the 
PEGylated vector was not able to induce any effects in blood lipidic pattern. 
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Indeed, the concentration of total cholesterol, LDL-C and HDL-C in mice 
receiving PEG-HD-Ad-ApoA-I remained at levels comparable to those displayed 
by mice administered with PBS. On the other hand, mice treated with HD-Ad-
ApoA-I showed significant changes in these parameters. This observation is 
mirrored by the analysis of fat deposits accumulation at level of aortic arch and 
abdominal aorta. In fact, untreated and PEG-HD-Ad-ApoA-I mice showed more 
consistent deposits in comparison to the group injected with HD-Ad-ApoA-I. This 
data can be explained by a putative different ability of PEG-HD-Ad-ApoA-I and 
HD-Ad-ApoA-I to infect tissues. In particular, the therapeutic effect of HD-Ad-
ApoA-I on atherosclerotic development strongly fit the ability of this vector to 
infect the mouse endothelium. Indeed, previously work (Gu, 2007) has shown that 
the expression of human ApoA-I in endothelial cells has a protective role on 
myocyte injury, suppressing the expression of ICAM-1 on endothelium, thus 
diminishing neutrophil adherence and transendothelial migration. In our case, it is 
possible that the binding of PEG to capsid proteins of HD-Ad vectors may hamper 
the endothelial infection by these vectors, compromising the transgene expression. 
In a complex pathology model, like our atherosclerotic mouse, a low expression 
of human ApoA-I in the endothelium would lead to a non-correction of 
pathological phenotype. On the other hand, higher endothelial expression of 
human ApoA-I with HD-Ad-ApoA-I would decrease the development of 
atherosclerotic lesion. In the end, our data clearly show that other factors are 
implied in the ability of PEGylated vector to revert the pathological phenotype 
examined, even if PEG-HD-Ad is able to reduce innate immune response and is 
effective to infect the liver after a systemic administration.  
However, in order to confirm our hypothesis, it would be necessary to perform a 
study of biodistrubution of PEG-HD-Ad vectors and analyze the transgene 
expression profile in different tissues before considering the eventuality to use 
them in clinical trials for correcting genetic diseases. 
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